OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
LQDA$61.9759

Liquidia Corp

PharmaceuticalsVerified

Liquidia Corp has a high price-to-book ratio of 123.11, indicating that the market is valuing the company significantly above its book value. The company's liquidity position is characterized by a current ratio of 2.01, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash is negative after subtracting total debt, which raises concerns about its liquidity. In terms of profitability, Liquidia Corp is currently unprofitable, with a net loss of $68.92 million and an operating loss of $51.38 million. The company's return on equity is -1.54, and its return on assets is -0.21, both of which are negative and indicate poor performance relative to its equity and asset base. The company's gross profit margin is 91.6%, which is high, but this is offset by significant operating and net losses. Liquidia Corp's revenue is concentrated in a single business segment, as disclosed in its financial statements. The company does not provide detailed geographic revenue breakdowns, but it is primarily focused on the U.S. market. This concentration increases the company's exposure to market-specific risks and regulatory changes. The company's growth trajectory is uncertain, as it has not provided specific revenue growth projections for the current or next fiscal year. The company's operating cash flow is negative at -$35.69 million, and its free cash flow is also negative at -$74.14 million. These figures suggest that the company is not generating sufficient cash from operations to fund its activities and may need to rely on external financing. The risk assessment for Liquidia Corp indicates a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio is 4.28, which is high and suggests that it is heavily leveraged. The key risk flag is the negative net cash position after subtracting total debt, which could impact the company's ability to meet its obligations. Recent events include the company's financial performance as reported in its latest financial statements. The company has not disclosed any major new product launches or strategic partnerships in the recent period. The company's stock is currently trading at $61.97, with a market capitalization of $5.51 billion. Analysts have provided a range of price targets, with a mean of $50.67 and a median of $54.00, indicating a generally bearish outlook.

30-day price · LQDA+22.13 (+57.0%)
Low$35.80High$62.30Close$60.98As of22 May, 00:00 UTC
Profile
CompanyLiquidia Corp
TickerLQDA.O
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Liquidia Corp is a biopharmaceutical company focused on the development and commercialization of inhaled and injectable therapeutics for the treatment of critical care and orphan diseases.

Classification. Liquidia Corp is classified under the Healthcare economic sector, Pharmaceuticals & Medical Research business sector, and the Pharmaceuticals industry with a confidence level of 0.92.

Liquidia Corp has a high price-to-book ratio of 123.11, indicating that the market is valuing the company significantly above its book value. The company's liquidity position is characterized by a current ratio of 2.01, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash is negative after subtracting total debt, which raises concerns about its liquidity. In terms of profitability, Liquidia Corp is currently unprofitable, with a net loss of $68.92 million and an operating loss of $51.38 million. The company's return on equity is -1.54, and its return on assets is -0.21, both of which are negative and indicate poor performance relative to its equity and asset base. The company's gross profit margin is 91.6%, which is high, but this is offset by significant operating and net losses. Liquidia Corp's revenue is concentrated in a single business segment, as disclosed in its financial statements. The company does not provide detailed geographic revenue breakdowns, but it is primarily focused on the U.S. market. This concentration increases the company's exposure to market-specific risks and regulatory changes. The company's growth trajectory is uncertain, as it has not provided specific revenue growth projections for the current or next fiscal year. The company's operating cash flow is negative at -$35.69 million, and its free cash flow is also negative at -$74.14 million. These figures suggest that the company is not generating sufficient cash from operations to fund its activities and may need to rely on external financing. The risk assessment for Liquidia Corp indicates a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio is 4.28, which is high and suggests that it is heavily leveraged. The key risk flag is the negative net cash position after subtracting total debt, which could impact the company's ability to meet its obligations. Recent events include the company's financial performance as reported in its latest financial statements. The company has not disclosed any major new product launches or strategic partnerships in the recent period. The company's stock is currently trading at $61.97, with a market capitalization of $5.51 billion. Analysts have provided a range of price targets, with a mean of $50.67 and a median of $54.00, indicating a generally bearish outlook.
Key takeaways
  • Liquidia Corp is currently unprofitable with significant operating and net losses.
  • The company has a high price-to-book ratio, indicating a premium valuation relative to its book value.
  • The company's liquidity position is moderate, but its net cash is negative after subtracting total debt.
  • The company's growth trajectory is uncertain, with no specific revenue growth projections provided.
  • The company's debt-to-equity ratio is high, indicating a significant reliance on debt financing.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$158.3M
Gross profit$145.1M
Operating income-$51.4M
Net income-$68.9M
R&D
SG&A
D&A
SBC
Operating cash flow-$35.7M
CapEx-$6.3M
Free cash flow-$74.1M
Total assets$327.9M
Total liabilities$283.2M
Total equity$44.7M
Cash & equivalents$190.7M
Long-term debt$191.3M
Valuation
Market price$61.97
Market cap$5.51B
Enterprise value$5.51B
P/E
Reported non-GAAP P/E
EV/Revenue34.8
EV/Op income
EV/OCF
P/B123.1
P/Tangible book123.1
Tangible book$44.7M
Net cash-$661.0k
Current ratio2.0
Debt/Equity4.3
ROA-21.0%
ROE-1.5%
Cash conversion52.0%
CapEx/Revenue-4.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricLQDAActivity
Op margin-32.5%7.7% medp25 -2.4% · p75 15.5%bottom quartile
Net margin-43.5%5.9% medp25 -3.8% · p75 12.8%bottom quartile
Gross margin91.6%45.5% medp25 31.1% · p75 62.9%top quartile
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-4.0%-7.0% medp25 -14.9% · p75 -3.2%above median
Debt / equity428.0%25.0% medp25 3.8% · p75 63.3%top quartile
Observations
IR observations
Mean price target50.67 USD
Median price target54.00 USD
High price target67.00 USD
Low price target19.00 USD
Mean recommendation1.89 (1=strong buy, 5=strong sell)
Strong-buy count4.00
Buy count4.00
Hold count0.00
Sell count0.00
Strong-sell count1.00
Mean EPS estimate2.65 USD
Last actual EPS-0.83 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-23 09:20 UTC#99e5584a
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 11:11 UTCJob: 78e9f75c